Featured content in this Issue: Companies, organisations and drug candidates mentioned in this Bulletin: EQUULUS Therapeutics; EQL-101; EQL-201; Gilgamesh Pharmaceuticals; DemeRx; atai Life Sciences; Delix Therapeutics; CaaMTech; Lykos Therapeutics; Beckley Psytech; BPL-003; Compass Pathways; Clairvoyant Therapeutics. This is the first issue of our Psychedelic Bulletin that’s exclusively…

Source

Previous articleDecolonization, Difficult Conversations, and the Challenge of Merging Spirituality and Science
Next articleThe Ketamine Conundrum